H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $4 from $2 and keeps a Buy rating on the shares. The company’s OV4071 oral KCC2 candidate is entering the clinic imminently, triggering warrant exercises, the analyst tells investors in a research note. The firm says Ovid has multiple additional potential therapeutic applications slated to be explored with its KCC2 portfolio candidates. H.C. Wainwright cites increased confidence in OV329 for the target doubling.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- 3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts
- Ovid Therapeutics price target raised to $7 from $5 at Wedbush
- Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
- Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
- Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating